Base case outcomes and incremental cost-effectiveness ratios for non-dominated strategies in a representative city of 2.5 million individuals age 15–59 years, with 1.2% of the population IDU, and 6.5% and 35% prevalence of HIV and HCV among IDU, respectively.^*

HIV – human immunodeficiency virus; HCV – hepatitis C virus; LYs – life years; QALYs – quality-adjusted life-years; ICER – incremental cost-effectiveness ratio; IDU – injection drug user.

*

Outcomes for all strategies considered are shown in Table S3.

**

Frequencies considered were: Upon entry to ORT; “Annual” = Upon entry to ORT and annually while in ORT; “6 months” = Upon entry to ORT and every 6 months while in ORT; “3 months” = Upon entry to ORT and every 3 months while in ORT.

***

“Dominated” indicates that the strategy costs more and provides fewer benefits than another strategy or a combination of two strategies.

****

This strategy consists of baseline case detection rates in the IDU and non-IDU populations and no screening targeted to individuals in ORT.